{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:18:18Z","timestamp":1794028698349,"version":"4.8.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Ustekinumab is approved for the treatment of Crohn\u2019s disease [CD]. Systematically registered prospective real-world data are scarce. We therefore aimed to study the effectiveness, safety and usage of ustekinumab for CD in everyday practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We prospectively enrolled CD patients initiating ustekinumab in regular care between December 2016 and January 2019. Clinical (Harvey Bradshaw Index [HBI]), biochemical (C-reactive protein [CRP] and faecal calprotectin [FCP]), extra-intestinal manifestations and, peri-anal fistula activity, ustekinumab dosage, concomitant medication use, and adverse events were documented at weeks 0, 12, 24, and 52. The primary outcome was corticosteroid-free clinical remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 221 CD patients were included (98.6% anti-tumour necrosis factor [TNF] and 46.6% vedolizumab exposed) with a median follow-up of 52.0 weeks [interquartile range 49.3\u201358.4]. Corticosteroid-free clinical remission rates at weeks 24 and 52 were 38.2% and 37.1%, respectively. An initial dosing schedule of 8 weeks, compared to 12 weeks, correlated with a lower discontinuation rate [20.0% vs 42.6%, p = 0.01], but comparable corticosteroid-free clinical remission at week 52 (46.3% [q8w] vs 34.6% [q12w], p = 0.20). There was no clinical benefit of combination therapy after 52 weeks when compared to ustekinumab monotherapy [combi 40.6% vs mono 36.0%, p = 0.64]. At baseline, 28 patients had active peri-anal fistula, of whom 35.7% showed complete clinical resolution after 24 weeks. During follow-up we encountered six severe infections [3.5 per 100 patient-years], with all patients being on concomitant immunosuppressant therapies. Ustekinumab treatment discontinuation was observed in 75 [33.9%] patients mainly due to lack of response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Ustekinumab is a relatively safe and effective treatment option for CD patients with prior failure of anti-TNF and anti-integrin therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjz119","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T19:13:54Z","timestamp":1560453234000},"page":"33-45","source":"Crossref","is-referenced-by-count":171,"title":["Ustekinumab for Crohn\u2019s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1361-8868","authenticated-orcid":false,"given":"Vince B C","family":"Biemans","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands"},{"name":"Department of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E","family":"van der Meulen - de Jong","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine J","family":"van der Woude","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"L\u00f6wenberg","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Academic Medical Centre, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Dijkstra","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Oldenburg","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanne K H","family":"de Boer","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, Gastroenterology and Metabolism Research Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"van der Marel","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Haaglanden Medical Centre, the Hague, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander G L","family":"Bodelier","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amphia Hospital, Breda, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen M","family":"Jansen","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeoffrey J L","family":"Haans","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaline","family":"Theeuwen","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"de Jong","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie J","family":"Pierik","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hoentjen","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,14]]},"reference":[{"key":"2020040905052577700_CIT0001","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2020040905052577700_CIT0002","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.cgh.2012.02.004","article-title":"Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population","volume":"10","author":"Ha","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020040905052577700_CIT0003","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1080\/00365521.2017.1373847","article-title":"Ustekinumab use in Crohn\u2019s disease: a Canadian tertiary care centre experience","volume":"52","author":"Greenup","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"2020040905052577700_CIT0004","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.cgh.2017.03.032","article-title":"Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn\u2019s disease","volume":"15","author":"Battat","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020040905052577700_CIT0005","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/apt.14487","article-title":"Long-term efficacy and safety of ustekinumab in 122 refractory Crohn\u2019s disease patients: a multicentre experience","volume":"47","author":"Wils","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2020040905052577700_CIT0006","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/MIB.0000000000000842","article-title":"Ustekinumab for the treatment of refractory Crohn\u2019s disease: the Spanish experience in a large multicentre open-label cohort","volume":"22","author":"Khorrami","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2020040905052577700_CIT0007","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cgh.2015.09.018","article-title":"Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn\u2019s disease refractory to anti-tumor necrosis factor agents","volume":"14","author":"Wils","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020040905052577700_CIT0008","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.crohns.2014.06.005","article-title":"Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn\u2019s disease\u2013the McGill experience","volume":"8","author":"Kopylov","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2020040905052577700_CIT0009","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MIB.0000000000000624","article-title":"Patients with refractory Crohn\u2019s disease successfully treated with ustekinumab","volume":"22","author":"Harris","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2020040905052577700_CIT0010","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/apt.14016","article-title":"Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn\u2019s disease: real world experience from a multicentre cohort","volume":"45","author":"Ma","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2020040905052577700_CIT0011","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/ecco-jcc\/jjz080","article-title":"Long-term clinical effectiveness of ustekinumab in patients with Crohn\u2019s disease who failed biological therapies: a national cohort study","volume":"13","author":"Liefferinckx","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2020040905052577700_CIT0012","article-title":"Development and feasibility of a web-based registry for multicentre surveillance of effectiveness and safety of novel IBD-drugs in the Netherlands","volume":"5","author":"Biemans","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"2020040905052577700_CIT0013","doi-asserted-by":"crossref","first-page":"S055","DOI":"10.1093\/ecco-jcc\/jjx180.073","article-title":"DOP036 Ustekinumab for Crohn\u2019s disease: a nationwide real-life observational cohort study [ICC Case Series]","volume":"12","author":"Biemans","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2020040905052577700_CIT0014","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"2020040905052577700_CIT0015","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/MIB.0000000000001074","article-title":"Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe Crohn\u2019s disease: real-world experience from a multicenter cohort study","volume":"23","author":"Ma","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2020040905052577700_CIT0016","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/j.gastro.2018.01.043","article-title":"Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn\u2019s disease","volume":"154","author":"Adedokun","year":"2018","journal-title":"Gastroenterology"},{"key":"2020040905052577700_CIT0017","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/ecco-jcc\/jjz008","article-title":"Ustekinumab exposure\u2013outcome analysis in Crohn\u2019s disease only in part explains limited endoscopic remission rates","volume":"13","author":"Verstockt","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2020040905052577700_CIT0018","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2020040905052577700_CIT0019","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/00365521.2014.928901","article-title":"Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?","volume":"50","author":"Gisbert","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"2020040905052577700_CIT0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"2020040905052577700_CIT0021","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/S0016-5085(17)30930-7","article-title":"Fistula healing in pivotal studies of ustekinumab","volume":"152","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"key":"2020040905052577700_CIT0022"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjz119\/28969995\/jjz119.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/1\/33\/33028815\/jjz119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/1\/33\/33028815\/jjz119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T09:05:51Z","timestamp":1586423151000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/14\/1\/33\/5521005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,14]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,6,14]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz119","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2019,6,14]]}}}